The Health Access and Recovery Peer Program (HARP)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Persons with serious mental illnesses (SMI) face elevated rates of medical comorbidity, and also challenges in effectively managing these health problems. There is an urgent need to develop self-management strategies that allow persons with SMI to more effectively manage their chronic medical illnesses.
In general populations, peer-led disease self-management interventions have been demonstrated to be feasible, effective, scalable, and to lead to sustainable improvements in self-management and health outcomes. With funding from an R34 intervention development grant from NIMH, the study team has developed and piloted a modified version of the most widely tested and used peer-led self management program, the Chronic Disease Self-Management Program (CDSMP), for persons with serious mental illness. Two pilot tests of this intervention, the Health and Recovery Peer (HARP) program, demonstrated that the program can be implemented with high engagement, retention, and program fidelity, and can result in effect sizes across a range of outcomes comparable to or greater than those seen in general medical populations.
This application proposes to conduct a fully-powered, multisite trial of the HARP program. A total of 400 individuals with serious mental illnesses and one or more chronic medical condition will be recruited from three diverse community mental health clinics in the Atlanta metro region and randomized to the HARP program or usual care. For individuals in the HARP program, two peer educators with SMI and one or more chronic medical condition will lead a six-session, six-week manualized intervention, which helps participants become more effective managers of their chronic illnesses. Follow-up interviews and chart reviews at 3 months, 6 months and one year will assess changes in clinical outcomes, improvement in generic and disease-specific measures of illness self-management, and quality of care. During the final phase of the study, a dissemination strategy building on the CDSMP training infrastructure will allow program participants to lead HARP groups.
If successful, this study will establish the first fully peer-led, evidence-based intervention for improving physical self-management in this vulnerable population.
| Condition | Intervention | Phase |
|---|---|---|
|
Hypertension Arthritis Coronary Artery Disease Hepatitis Diabetes Asthma Hyperlipidemia HIV |
Behavioral: HARP Intervention |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Single Blind (Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | A Peer-Led, Medical Disease Self-Management Program for Mental Health Consumers |
- Health related quality of life [ Time Frame: One Year ] [ Designated as safety issue: No ]
- Behavioral Activation [ Time Frame: One Year ] [ Designated as safety issue: No ]Behavioral Activation will be measured using the Patient Activation Measure, an instrument which has been found to be reliable and valid across a wide range of patient populations.
- Health Behaviors [ Time Frame: One Year ]Health behaviors
| Estimated Enrollment: | 400 |
| Study Start Date: | June 2011 |
| Estimated Study Completion Date: | April 2016 |
| Estimated Primary Completion Date: | April 2015 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: HARP Intervention |
Behavioral: HARP Intervention
The HARP intervention is a 6-week, 6-session, group format intervention to improve self-management of chronic medical diseases. Each group lasts 90 minutes and has 8-12 attendees. Between groups, participants work with partners from the group to troubleshoot problems and accomplish action plans identified during the session. At the end of the program, monthly alumni groups meet for six months to reinforce lessons from the intervention, monitor progress, and maintain peer support.
|
| No Intervention: No Intervention: Control |
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- On CMHC roster of active patients.
- Presence of a serious mental illness (schizophrenia, schizoaffective disorder, bipolar disorder, major depression, obsessive-compulsive disorder, or post-traumatic stress disorder
- Chronic Medical Condition as noted in the CMHC chart or via self-report: (hypertension; arthritis; heart disease; diabetes; and asthma/COPD),
Exclusion Criteria:
- cognitive impairment based on a score of > 3 on a 6-item, validated screener developed for clinical research
Contacts and Locations| Contact: Gretl Glick | 404-783-1061 | gglick@emory.edu |
| Contact: Silke von Esenwein, PhD | 404-712-8525 | svonese@emory.edu |
| United States, Georgia | |
| Central Fulton Community Mental Health Center at Grady Hospital | Recruiting |
| Atlanta, Georgia, United States, 30303 | |
| Contact: Gretl Glick 404-783-1061 gglick@emory.edu | |
| Principal Investigator: | Benjamin Druss, MD, MPH | Emory University |
More Information
No publications provided
| Responsible Party: | Benjamin Druss, Professor, Emory University |
| ClinicalTrials.gov Identifier: | NCT01725815 History of Changes |
| Other Study ID Numbers: | 1R01MH090584-01A1 |
| Study First Received: | April 25, 2012 |
| Last Updated: | March 7, 2013 |
| Health Authority: | United States: Federal Government |
Additional relevant MeSH terms:
|
Arthritis Asthma Coronary Artery Disease Myocardial Ischemia Coronary Disease Hepatitis Hepatitis A Hyperlipidemias Hypertension Joint Diseases Musculoskeletal Diseases Bronchial Diseases Respiratory Tract Diseases Lung Diseases, Obstructive Lung Diseases |
Respiratory Hypersensitivity Hypersensitivity, Immediate Hypersensitivity Immune System Diseases Heart Diseases Cardiovascular Diseases Arteriosclerosis Arterial Occlusive Diseases Vascular Diseases Liver Diseases Digestive System Diseases Hepatitis, Viral, Human Virus Diseases Enterovirus Infections Picornaviridae Infections |
ClinicalTrials.gov processed this record on May 23, 2013